Author

N. Bley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

D. Misiak· 2 shared S. Huettelmaier· 2 shared T. Fuchs· 2 shared A. Schott· 1 shared A. Sinz· 1 shared C. Assmann· 1 shared C. Ihling· 1 shared C. Thomssen· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Misiak

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

S. Hagemann, D. Misiak, J. L. Bell, T. Fuchs, M. I. Lederer, N. Bley, M. Haemmerle, E. Ghazy, W. Sippl, J. H. Schulte, S. Huettelmaier

This paper identifies a druggable feedforward loop between IGF2BP1 and MYCN in high-risk neuroblastoma that promotes oncogene expression and relapse, suggesting combined targeting as a therapeutic strategy.

bioRxiv · Mar 18, 2023Cancer Biology

IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer

N. Bley, A. Schott, S. Mueller, D. Misiak, M. Lederer, T. Fuchs, C. Assmann, M. Glass, C. Ihling, A. Sinz, N. Pazaitis, C. Wickenhauser, M. Vetter, O. Ungurs, H.-G. Strauss, , S. Huettelmaier

This study identifies IGF2BP1 as a driver of invasive growth in ovarian cancer through SRC/MAPK signaling, showing that combinatorial SRC/MEK inhibition is effective in treating mesenchymal-like HG-SOC.

bioRxiv · Jun 19, 2020Cancer Biology